1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. ImmunoPrecise Antibodies Ltd.
  6. News
  7. Summary
    IPA   CA45257F2008

IMMUNOPRECISE ANTIBODIES LTD.

(IPA)
  Report
Delayed Bourse de Toronto  -  03:58 2022-06-29 pm EDT
4.800 CAD   -4.76%
06/01Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, ABSI, APVO)
AQ
05/27IMMUNOPRECISE ANTIBODIES : Investor Presentation June 2022
PU
05/25Biotech Recovery Accelerates These Companies Benefit (IPA, SIGA, MNKD, INO, CTIC)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ImmunoPrecise Antibodies : Investor Presentation June 2022

05/27/2022 | 08:03am EDT

Winning the

RACE

For precision medicine.

June 2022 NASDAQ:IPA

Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the "Company") securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company's securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company's potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements, including future-oriented financial information ("FOFI"). Forward-looking statements can generally be identified by the use of language such as "may", "expect", "estimate", "anticipate", "intend", "believe", "potential" & "continue" or the negative thereof or similar variations. Forward- looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company's management about the Company's business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation. The Company undertakes no obligation to update or revise these forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. Inevitably, some assumptions will not materialize, & anticipated events & circumstances may affect the ultimate financial results. Projections are inherently subject to substantial & numerous uncertainties & to a wide variety of significant business, economic & competitive risks, & the assumptions underlying the projections may be inaccurate in any material respect, including, but not limited to, those risks set forth in the Company's Management Discussion & Analysis for the year ended April 30, 2021, a copy of which may be obtained from SEDAR.com. The purpose of FOFI provided in this presentation is to provide prospective investors with information pertaining to the Company's long-term business objectives. Readers are cautioned that this information may not be appropriate for other purposes.

2

The Opportunity

The HUB of Biotherapeutic Intelligence

A hybrid of platforms and technologies in the SCIENCE and BUSINESS of therapeutic discovery.

LENSai

Engineered for the scientific race

A new lens on

Natural

Engineered for the clinical race

Antibody research & development

biotherapeutic

Artificial

Licensing

Protein manufacturing

intelligence:

Complex

Partnership

BioStrand

©2022 IPA. All rights reserved. CONFIDENTIAL

Engineered for the race and the shared pursuit of clinical success.

3

The Problem

Matching the mutation to the therapy

THE PROBLEM

The Problem

Matching the mutation to the therapy - need for rapid and accurate solutions for personalized medicine

The central challenges of

From sequence ... to therapy.

computational biology are to:

  • Analyze massive multi-omic datasets to determine sequence and structural basis of disease, identify targets
  • Rapidly analyze structural target data
    to inform the design of safe and efficacious therapies
  • Accurately match individualized therapies to patients based on structural and functional characteristics of target

©2022 IPA. All rights reserved. CONFIDENTIAL

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

ImmunoPrecise Antibodies Ltd. published this content on 27 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 May 2022 12:02:14 UTC.


© Publicnow 2022
All news about IMMUNOPRECISE ANTIBODIES LTD.
06/01Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, ..
AQ
05/27IMMUNOPRECISE ANTIBODIES : Investor Presentation June 2022
PU
05/25Biotech Recovery Accelerates These Companies Benefit (IPA, SIGA, MNKD, INO, CTIC)
AQ
05/09ImmunoPrecise Subsidiary BioStrand Secures Second VLAIO Research Grant
MT
05/09IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant
BU
05/09ImmunoPrecise Antibodies Announces Departure of Stefan Lang, Chief Business Officer
CI
04/25IMMUNOPRECISE ANTIBODIES : Form 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
04/21IPA's Advanced PolyTope TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro ..
AQ
04/20IMMUNOPRECISE ANTIBODIES : IPA's Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Po..
PU
04/20IPA's Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro..
BU
More news
Financials
Sales 2022 19,1 M 14,8 M 14,8 M
Net income 2022 -15,9 M -12,3 M -12,3 M
Net Debt 2022 - - -
P/E ratio 2022 -5,85x
Yield 2022 -
Capitalization 113 M 87,6 M 87,6 M
Capi. / Sales 2022 5,91x
Capi. / Sales 2023 4,85x
Nbr of Employees 73
Free-Float 94,3%
Chart IMMUNOPRECISE ANTIBODIES LTD.
Duration : Period :
ImmunoPrecise Antibodies Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNOPRECISE ANTIBODIES LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 4,80 CAD
Average target price 12,00 CAD
Spread / Average Target 150%
EPS Revisions
Managers and Directors
Jennifer Bath President, Chief Executive Officer & Director
Lisa Helbling Chief Financial Officer
James S. Kuo Chairman
Ilse Roodink Chief Scientific Officer
Gregory S. Smith Independent Director
Sector and Competitors